Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase 3, double-blind, placebo-controlled study of the efficacy and safety of lonidamine for the treatment of symptomatic benign prostatic hyperplasia

Next Previous
X
Search
Trial Profile

A randomized phase 3, double-blind, placebo-controlled study of the efficacy and safety of lonidamine for the treatment of symptomatic benign prostatic hyperplasia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonidamine (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Threshold Pharmaceuticals

    • Most Recent Events

    • 07 Sep 2024 This trialhas been completed in Hungary, according to European Clinical Trials Database record.
    • 19 Oct 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004110).
    • 08 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top